Hepatocellular carcinoma (HCC) is a heterogeneous cancer with variable outcomes after treatment. Prognosis of HCC cannot be accurately predicted by current clinical staging systems. Development of prognostic biomarkers is critical to improve treatment outcome. Recent studies indicate that inflammatory and immunological markers might provide reliable prognostic classification in HCC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sieghart, W. et al. A single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of hepatocellular carcinoma. Hepatology http://dx.doi.org/10.1002/hep.26057.
Fu, J. et al. The impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology http://dx.doi.org/10.1002/hep.26054.
Hashimoto, K. et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103, 1856–1864 (2005).
An, H. J. et al. Serum C-reactive protein is a useful biomarker to predict outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. http://dx.doi.org/10.1002/lt.23512.
Jang, J. W. et al. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine http://dx.doi.org/10.1016/j.cyto.2012.07.117.
Fu, J. et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132, 2328–2339 (2007).
Zhou, J. et al. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int. J. Cancer 125, 1640–1648 (2009).
Pedroza-Gonzalez, A. et al. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology http://dx.doi.org/10.1002/hep.26013.
Greten, T. F. et al. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J. Immunother. 33, 211–218 (2010).
Pang, R. W. et al. Biology of hepatocellular carcinoma. Ann. Surg. Oncol. 15, 962–971 (2008).
Acknowledgements
The authors would like to acknowledge grant support from the Strategic Research Theme Grant of the Centre for Cancer Research of the Faculty of Medicine, The University of Hong Kong.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Pang, R., Poon, R. Novel prognostic biomarkers in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 9, 691–692 (2012). https://doi.org/10.1038/nrgastro.2012.208
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2012.208
